| 2025-11-28 |
详情>>
股本变动：
变动后总股本19107.75万股
|
| 2025-10-29 |
复牌提示：
2025-10-28 15:04:15 停牌，复牌日期 2025-10-28 15:09:15
|
| 2025-10-20 |
股东大会：
将于2025-11-27召开股东大会
会议内容 ▼▲
- 1.Approval of the compensation policy for the Chief Executive Officer for the 2025 financial year (applicable from November 27 to December 31);
2.Approval of the settlement agreement entered into between the Company and Mr. Frédéric Cren in accordance with Articles L. 225-38 et seq. of the French Commercial Code;
3.Partial waiver of the attendance and performance conditions associated with the grant of free shares to Mr. Frédéric Cren under the AGA 2024-1 and AGA 2025-1 plans;
4.Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options;
5.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the Company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights;
6.Powers to carry out formalities.
|
| 2025-10-20 |
股东大会：
将于2025-11-27召开股东大会
会议内容 ▼▲
- 1.Approval of the compensation policy for the Chief Executive Officer for the 2025 financial year (applicable from November 27 to December 31);
2.Approval of the settlement agreement entered into between the Company and Mr. Frédéric Cren in accordance with Articles L. 225-38 et seq. of the French Commercial Code;
3.Partial waiver of the attendance and performance conditions associated with the grant of free shares to Mr. Frédéric Cren under the AGA 2024-1 and AGA 2025-1 plans;
4.Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options;
5.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the Company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights;
6.Powers to carry out formalities.
|
| 2025-10-14 |
详情>>
业绩披露：
2025年中报每股收益-1.62欧元,归母净利润-1.76亿欧元,同比去年增长-258.73%
|
| 2025-04-15 |
详情>>
业绩披露：
2024年年报每股收益-3.08欧元,归母净利润-1.84亿欧元,同比去年增长-66.82%
|
| 2025-04-11 |
股东大会：
将于2025-05-22召开股东大会
会议内容 ▼▲
- 1.Approval of the statutory financial statements for the financial year ended December 31, 2024;
2.Approval of the consolidated financial statements for the financial year ended December 31, 2024;
3.Appropriation of profit/loss for the financial year ended December 31, 2024;
4.Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code;
5.Approval of the subscription agreement for royalty certificates issued by the Company signed on July 17, 2024 between the Company and Biotechnology Value Fund Partners L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
6.Approval of the subscription agreement for new shares and pre-funded warrants issued by the Company signed on October 17, 2024 between the Company and Biotechnology Value Fund Partners L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
7.Approval of the transfer of know-how and communication agreement signed on December 11, 2024 between the Company and its Deputy Chief Executive Officer, in accordance with Articles L.225-38 et seq. of the French Commercial Code;
8.Approval of the subscription agreement for new shares issued by the Company signed on December 13, 2024 between the Company and Samsara BioCapital L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
9.Approval of the subscription agreement for pre-funded warrants issued by the Company signed on December 13, 2024 between the Company and Samsara BioCapital L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
10.Final approval of the fixed and variable compensation paid or awarded to Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors for the financial year ended December 31, 2024 (from December 13, 2024);
11.Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer until December 13, 2024 and as Chief Executive Officer from December 13, 2024 for the financial year ended December 31, 2024;
12.Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31, 2024;
13.Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code;
14.Approval of the compensation policy for Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors;
15.Approval of the compensation policy for Mr. Frédéric Cren in his capacity as Chief Executive Officer;
16.Approval of the compensation policy for Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer;
17.Total compensation paid to members of the Board of Directors;
18.Approval of the compensation policy of the Company's directors;
19.Appointment of Ms. Renée Aguiar-Lucander, as Director of the Company;
20.Renewal of the Director's mandate of Mr. Frédéric Cren;
21.Renewal of the Director's mandate of Cell+;
22.Authorization granted to the Board of Directors to buyback the Company's shares;
23.Authorization to the Board of Directors to reduce the share capital by cancellation of shares;
24.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders’ preemptive subscription rights maintained;
25.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2- 1° of the French Code monétaire et financier;
26.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French Code monétaire et financier;
27.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders’ preemptive subscription rights;
28.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in favor of one or more persons specifically designated by the Board of Directors, without shareholders’ preemptive subscription rights;
29.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the U.S. market called "At-the-market" or "ATM", without shareholders’ preemptive subscription rights;
30.Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders’ preemptive subscription rights;
31.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company;
32.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind within the limits set by legal and regulatory provisions, excluding the case of a public exchange offer initiated by the Company;
33.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights;
34.Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums;
35.Decision to be taken in application of article L. 225-248 of the French Commercial Code (shareholders' equity less than half the share capital);
36.Harmonization of the articles of association of the Company with applicable laws and regulations, including some provisions of the French Law no. 2024-537 of June 13, 2024 aimed at increasing business financing and France's attractiveness;
37.Power for formalities.
|
| 2025-04-11 |
股东大会：
将于2025-05-22召开股东大会
会议内容 ▼▲
- 1.Approval of the statutory financial statements for the financial year ended December 31, 2024;
2.Approval of the consolidated financial statements for the financial year ended December 31, 2024;
3.Appropriation of profit/loss for the financial year ended December 31, 2024;
4.Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code;
5.Approval of the subscription agreement for royalty certificates issued by the Company signed on July 17, 2024 between the Company and Biotechnology Value Fund Partners L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
6.Approval of the subscription agreement for new shares and pre-funded warrants issued by the Company signed on October 17, 2024 between the Company and Biotechnology Value Fund Partners L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
7.Approval of the transfer of know-how and communication agreement signed on December 11, 2024 between the Company and its Deputy Chief Executive Officer, in accordance with Articles L.225-38 et seq. of the French Commercial Code;
8.Approval of the subscription agreement for new shares issued by the Company signed on December 13, 2024 between the Company and Samsara BioCapital L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
9.Approval of the subscription agreement for pre-funded warrants issued by the Company signed on December 13, 2024 between the Company and Samsara BioCapital L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;
10.Final approval of the fixed and variable compensation paid or awarded to Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors for the financial year ended December 31, 2024 (from December 13, 2024);
11.Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer until December 13, 2024 and as Chief Executive Officer from December 13, 2024 for the financial year ended December 31, 2024;
12.Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31, 2024;
13.Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code;
14.Approval of the compensation policy for Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors;
15.Approval of the compensation policy for Mr. Frédéric Cren in his capacity as Chief Executive Officer;
16.Approval of the compensation policy for Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer;
17.Total compensation paid to members of the Board of Directors;
18.Approval of the compensation policy of the Company's directors;
19.Appointment of Ms. Renée Aguiar-Lucander, as Director of the Company;
20.Renewal of the Director's mandate of Mr. Frédéric Cren;
21.Renewal of the Director's mandate of Cell+;
22.Authorization granted to the Board of Directors to buyback the Company's shares;
23.Authorization to the Board of Directors to reduce the share capital by cancellation of shares;
24.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders’ preemptive subscription rights maintained;
25.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2- 1° of the French Code monétaire et financier;
26.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French Code monétaire et financier;
27.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders’ preemptive subscription rights;
28.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in favor of one or more persons specifically designated by the Board of Directors, without shareholders’ preemptive subscription rights;
29.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the U.S. market called "At-the-market" or "ATM", without shareholders’ preemptive subscription rights;
30.Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders’ preemptive subscription rights;
31.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company;
32.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind within the limits set by legal and regulatory provisions, excluding the case of a public exchange offer initiated by the Company;
33.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights;
34.Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums;
35.Decision to be taken in application of article L. 225-248 of the French Commercial Code (shareholders' equity less than half the share capital);
36.Harmonization of the articles of association of the Company with applicable laws and regulations, including some provisions of the French Law no. 2024-537 of June 13, 2024 aimed at increasing business financing and France's attractiveness;
37.Power for formalities.
|
| 2024-11-14 |
股东大会：
将于2024-12-11召开股东大会
会议内容 ▼▲
- 1.Appointment of Mr. Mark Pruzanski, as Director of the Company;
2.Appointment of Mr. Srinivas Akkaraju, as Director of the Company;
3.Approval of the compensation policy for the Chief Executive Officer (application from the date of separation of functions);
4.Approval of the compensation policy of the Chairperson of the Board of Directors (application from the date of separation of functions);
5.Capital increase in cash for a nominal amount of EUR 78,720.64 by issuance of ordinary shares, without shareholders’ preemptive subscription rights to the benefit of named persons and delegation of authority to the Board of Directors;
6.Cancellation of the preemptive subscription rights for New Enterprise Associates 17, L.P.;
7.Cancellation of the preemptive subscription rights for Growth Equity Opportunities 18 VGE, LLC;
8.Cancellation of the preemptive subscription rights for Sofinnova Crossover I SLP;
9.Cancellation of the preemptive subscription rights for Yiheng Capital Management, L.P.;
10.Cancellation of the preemptive subscription rights for BioDiscovery 6 FPCI;
11.Cancellation of the preemptive subscription rights for Invus Public Equities, L.P.;
12.Cancellation of the preemptive subscription rights for Samsara BioCapital, L.P.;
13.Cancellation of the preemptive subscription rights for Perceptive Life Sciences Master Fund, Ltd.;
14.Cancellation of the preemptive subscription rights for CVI Investments Inc.;
15.Cancellation of the preemptive subscription rights for Biomedical Value Fund, L.P.;
16.Cancellation of the preemptive subscription rights for Biomedical Offshore Value Fund, L.P.;
17.Cancellation of the preemptive subscription rights for Schonfeld Global Master Fund, L.P.;
18.Cancellation of the preemptive subscription rights for Eventide Healthcare Innovation Fund I, L.P.;
19.Cancellation of the preemptive subscription rights for Adage Capital Partners, L.P.;
20.Cancellation of the preemptive subscription rights for Altamont Pharmaceutical Holdings, LLC;
21.Cancellation of the preemptive subscription rights for Albemarle Life Sciences Fund, sub-fund of Avondale ICAV;
22.Cancellation of the preemptive subscription rights for KVP Capital, LP;
23.Decision to issue 8,053,847 pre-funded warrants of the Company without shareholders’ preemptive subscription rights to the benefit of named persons and delegation of authority to the Board of Directors;
24.Cancellation of the preemptive subscription rights for Biotechnology Value Fund, L.P. ;
25.Cancellation of the preemptive subscription rights for Biotechnology Value Fund II, L.P. ;
26.Cancellation of the preemptive subscription rights for Biotechnology Value Trading Fund OS, L.P. ;
27.Cancellation of the preemptive subscription rights for MSI BVF SPV, LLC ;
28.Cancellation of the preemptive subscription rights for New Enterprise Associates 17, L.P.;
29.Cancellation of the preemptive subscription rights for Growth Equity Opportunities 18 VGE, LLC;
30.Cancellation of the preemptive subscription rights for Samsara BioCapital, L.P.;
31.Cancellation of the preemptive subscription rights for Perceptive Life Sciences Master Fund, Ltd.;
32.Cancellation of the preemptive subscription rights for Deep Track Biotechnology Master Fund, Ltd.;
33.Capital increase by issuance of shares with warrants attached, without shareholders’ preemptive subscription rights to the benefit of named persons and delegation of authority to the Board of Directors;
34.Cancellation of the preemptive subscription rights for Sofinnova Crossover I SLP;
35.Cancellation of the preemptive subscription rights for Yiheng Capital Management, L.P.;
36.Cancellation of the preemptive subscription rights for BioDiscovery 6 FPCI;
37.Cancellation of the preemptive subscription rights for Invus Public Equities, L.P.;
38.Cancellation of the preemptive subscription rights for Samsara BioCapital, L.P.;
39.Cancellation of the preemptive subscription rights for Perceptive Life Sciences Master Fund, Ltd.;
40.Cancellation of the preemptive subscription rights for CVI Investments Inc.;
41.Cancellation of the preemptive subscription rights for Biomedical Value Fund, L.P.;
42.Cancellation of the preemptive subscription rights for Biomedical Offshore Value Fund, L.P.;
43.Cancellation of the preemptive subscription rights for Schonfeld Global Master Fund, L.P.;
44.Cancellation of the preemptive subscription rights for Eventide Healthcare Innovation Fund I, L.P.;
45.Cancellation of the preemptive subscription rights for Adage Capital Partners, L.P.;
46.Cancellation of the preemptive subscription rights for Altamont Pharmaceutical Holdings, LLC;
47.Cancellation of the preemptive subscription rights for Albemarle Life Sciences Fund, sub-fund of Avondale ICAV;
48.Cancellation of the preemptive subscription rights for KVP Capital, LP;
49.Decision to issue pre-funded warrants with share subscription warrants attached, without shareholders’ preemptive subscription rights to the benefit of named persons and delegation of authority to the Board of Directors;
50.Cancellation of the preemptive subscription rights for Biotechnology Value Fund, L.P.;
51.Cancellation of the preemptive subscription rights for Biotechnology Value Fund II, L.P.;
52.Cancellation of the preemptive subscription rights for Biotechnology Value Trading Fund OS, L.P.;
53.Cancellation of the preemptive subscription rights for MSI BVF SPV, LLC;
54.Cancellation of the preemptive subscription rights for New Enterprise Associates 17, L.P.;
55.Cancellation of the preemptive subscription rights for Growth Equity Opportunities 18 VGE, LLC;
56.Cancellation of the preemptive subscription rights for Perceptive Life Sciences Master Fund, Ltd.;
57.Cancellation of the preemptive subscription rights for Deep Track Biotechnology Master Fund, Ltd.;
58.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders’ preemptive subscription rights;
59.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the Company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights;
60.Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers;
61.Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options;
62.Delegation of authority to the Board of Directors to decide on the issuance of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons;
63.Modification of the overall limit on the maximum authorized amounts set under the resolutions twenty-first to twenty-third, twenty-sixth, twenty-eighth and twenty-ninth resolutions of the General Meeting of June 20, 2024;
64.Amendment of the compensation policy for the Company’s directors;
65.Powers to carry out formalities.
|
| 2024-11-14 |
股东大会：
将于2024-12-11召开股东大会
会议内容 ▼▲
- 1.Appointment of Mr. Mark Pruzanski, as Director of the Company;
2.Appointment of Mr. Srinivas Akkaraju, as Director of the Company;
3.Approval of the compensation policy for the Chief Executive Officer (application from the date of separation of functions);
4.Approval of the compensation policy of the Chairperson of the Board of Directors (application from the date of separation of functions);
5.Capital increase in cash for a nominal amount of EUR 78,720.64 by issuance of ordinary shares, without shareholders’ preemptive subscription rights to the benefit of named persons and delegation of authority to the Board of Directors;
6.Cancellation of the preemptive subscription rights for New Enterprise Associates 17, L.P.;
7.Cancellation of the preemptive subscription rights for Growth Equity Opportunities 18 VGE, LLC;
8.Cancellation of the preemptive subscription rights for Sofinnova Crossover I SLP;
9.Cancellation of the preemptive subscription rights for Yiheng Capital Management, L.P.;
10.Cancellation of the preemptive subscription rights for BioDiscovery 6 FPCI;
11.Cancellation of the preemptive subscription rights for Invus Public Equities, L.P.;
12.Cancellation of the preemptive subscription rights for Samsara BioCapital, L.P.;
13.Cancellation of the preemptive subscription rights for Perceptive Life Sciences Master Fund, Ltd.;
14.Cancellation of the preemptive subscription rights for CVI Investments Inc.;
15.Cancellation of the preemptive subscription rights for Biomedical Value Fund, L.P.;
16.Cancellation of the preemptive subscription rights for Biomedical Offshore Value Fund, L.P.;
17.Cancellation of the preemptive subscription rights for Schonfeld Global Master Fund, L.P.;
18.Cancellation of the preemptive subscription rights for Eventide Healthcare Innovation Fund I, L.P.;
19.Cancellation of the preemptive subscription rights for Adage Capital Partners, L.P.;
20.Cancellation of the preemptive subscription rights for Altamont Pharmaceutical Holdings, LLC;
21.Cancellation of the preemptive subscription rights for Albemarle Life Sciences Fund, sub-fund of Avondale ICAV;
22.Cancellation of the preemptive subscription rights for KVP Capital, LP;
23.Decision to issue 8,053,847 pre-funded warrants of the Company without shareholders’ preemptive subscription rights to the benefit of named persons and delegation of authority to the Board of Directors;
24.Cancellation of the preemptive subscription rights for Biotechnology Value Fund, L.P. ;
25.Cancellation of the preemptive subscription rights for Biotechnology Value Fund II, L.P. ;
26.Cancellation of the preemptive subscription rights for Biotechnology Value Trading Fund OS, L.P. ;
27.Cancellation of the preemptive subscription rights for MSI BVF SPV, LLC ;
28.Cancellation of the preemptive subscription rights for New Enterprise Associates 17, L.P.;
29.Cancellation of the preemptive subscription rights for Growth Equity Opportunities 18 VGE, LLC;
30.Cancellation of the preemptive subscription rights for Samsara BioCapital, L.P.;
31.Cancellation of the preemptive subscription rights for Perceptive Life Sciences Master Fund, Ltd.;
32.Cancellation of the preemptive subscription rights for Deep Track Biotechnology Master Fund, Ltd.;
33.Capital increase by issuance of shares with warrants attached, without shareholders’ preemptive subscription rights to the benefit of named persons and delegation of authority to the Board of Directors;
34.Cancellation of the preemptive subscription rights for Sofinnova Crossover I SLP;
35.Cancellation of the preemptive subscription rights for Yiheng Capital Management, L.P.;
36.Cancellation of the preemptive subscription rights for BioDiscovery 6 FPCI;
37.Cancellation of the preemptive subscription rights for Invus Public Equities, L.P.;
38.Cancellation of the preemptive subscription rights for Samsara BioCapital, L.P.;
39.Cancellation of the preemptive subscription rights for Perceptive Life Sciences Master Fund, Ltd.;
40.Cancellation of the preemptive subscription rights for CVI Investments Inc.;
41.Cancellation of the preemptive subscription rights for Biomedical Value Fund, L.P.;
42.Cancellation of the preemptive subscription rights for Biomedical Offshore Value Fund, L.P.;
43.Cancellation of the preemptive subscription rights for Schonfeld Global Master Fund, L.P.;
44.Cancellation of the preemptive subscription rights for Eventide Healthcare Innovation Fund I, L.P.;
45.Cancellation of the preemptive subscription rights for Adage Capital Partners, L.P.;
46.Cancellation of the preemptive subscription rights for Altamont Pharmaceutical Holdings, LLC;
47.Cancellation of the preemptive subscription rights for Albemarle Life Sciences Fund, sub-fund of Avondale ICAV;
48.Cancellation of the preemptive subscription rights for KVP Capital, LP;
49.Decision to issue pre-funded warrants with share subscription warrants attached, without shareholders’ preemptive subscription rights to the benefit of named persons and delegation of authority to the Board of Directors;
50.Cancellation of the preemptive subscription rights for Biotechnology Value Fund, L.P.;
51.Cancellation of the preemptive subscription rights for Biotechnology Value Fund II, L.P.;
52.Cancellation of the preemptive subscription rights for Biotechnology Value Trading Fund OS, L.P.;
53.Cancellation of the preemptive subscription rights for MSI BVF SPV, LLC;
54.Cancellation of the preemptive subscription rights for New Enterprise Associates 17, L.P.;
55.Cancellation of the preemptive subscription rights for Growth Equity Opportunities 18 VGE, LLC;
56.Cancellation of the preemptive subscription rights for Perceptive Life Sciences Master Fund, Ltd.;
57.Cancellation of the preemptive subscription rights for Deep Track Biotechnology Master Fund, Ltd.;
58.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders’ preemptive subscription rights;
59.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the Company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights;
60.Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers;
61.Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options;
62.Delegation of authority to the Board of Directors to decide on the issuance of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons;
63.Modification of the overall limit on the maximum authorized amounts set under the resolutions twenty-first to twenty-third, twenty-sixth, twenty-eighth and twenty-ninth resolutions of the General Meeting of June 20, 2024;
64.Amendment of the compensation policy for the Company’s directors;
65.Powers to carry out formalities.
|
| 2024-10-15 |
详情>>
业绩披露：
2024年中报每股收益-0.94欧元,归母净利润-4902.9万欧元,同比去年增长11.29%
|
| 2024-09-25 |
财报披露：
美东时间 2024-09-25 盘前发布财报
|
| 2024-05-13 |
股东大会：
将于2024-06-20召开股东大会
会议内容 ▼▲
- 1.Approval of the statutory financial statements for the financial year ended December 31, 2023.
2.Approval of the consolidated financial statements for the financial year ended December 31, 2023.
3.Appropriation of profit/loss for the financial year ended December 31, 2023.
4.Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code.
5.Approval of the transfer of know-how and communication agreement signed on December 20, 2023 between the Company and its Deputy Chief Executive Officer, Chief Scientific Officer and director of the Company, Mr.Pierre Broqua, in accordance with Articles L.225-38 et seq.of the French Commercial Code.
6.Final approval of the fixed and variable compensation paid or awarded to Mr.Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer for the financial year ended December 31, 2023.
7.Amendment to the compensation policy for Mr.Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ending December 31, 2023.
8.Final approval of the fixed and variable compensation paid or awarded to Mr.Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31, 2023.
9.Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I.of the French Commercial Code.
10.Approval of the compensation policy for Mr.Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer.
11.Approval of the compensation policy for Mr.Pierre Broqua in his capacity as Deputy Chief Executive Officer.
12.Total compensation paid to members of the Board of Directors.
13.Approval of the compensation policy of the Company's directors.
14.Appointment of Mr.André Turenne, as Director of the Company.
15.Renewal of the Director's mandate of Ms.Martine Zimmermann.
16.Renewal of the Director's mandate of Mr.Heinz Maeusli.
17.Renewal of the Director's mandate of Ms.Lucy Lu.
18.Renewal of the company KPMG as Statutory Auditor.
19.Authorization granted to the Board of Directors to buyback the Company's shares.
20.Authorization to the Board of Directors to reduce the share capital by cancellation of shares.
21.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders’ preemptive subscription rights maintained.
22Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2- 1 of the French Code monétaire et financier.
23.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1 of the French Code monétaire et financier.
24.Authorization and/or delegation to the Board of Directors to set the issuance price on the capital increases by way of public offerings, without shareholders’ preemptive rights, pursuant to the terms and conditions set by the General Shareholders' Meeting, and up to the limit provided for by the laws and regulations in force at the time of issue.
25.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders’ preemptive subscription rights.
26.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the U.S.market called "At-the-market" or "ATM", without shareholders’ preemptive subscription rights.
27.Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders’ preemptive subscription rights.
28.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company.
29.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind within the limits set by legal and regulatory provisions, excluding the case of a public exchange offer initiated by the Company.
30.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights.
31.Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums.
32.Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers.
33.Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options.
34.Delegation of authority to the Board of Directors to decide on the issue of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons.
35.Decision to be taken in application of article L. 225-248 of the French Commercial Code (shareholders' equity less than half the share capital).
36.Creation of a new article 23 "Censeur" (non-voting director).
37.Power for formalities.
|
| 2024-05-13 |
股东大会：
将于2024-06-20召开股东大会
会议内容 ▼▲
- 1.Approval of the statutory financial statements for the financial year ended December 31, 2023.
2.Approval of the consolidated financial statements for the financial year ended December 31, 2023.
3.Appropriation of profit/loss for the financial year ended December 31, 2023.
4.Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code.
5.Approval of the transfer of know-how and communication agreement signed on December 20, 2023 between the Company and its Deputy Chief Executive Officer, Chief Scientific Officer and director of the Company, Mr.Pierre Broqua, in accordance with Articles L.225-38 et seq.of the French Commercial Code.
6.Final approval of the fixed and variable compensation paid or awarded to Mr.Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer for the financial year ended December 31, 2023.
7.Amendment to the compensation policy for Mr.Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ending December 31, 2023.
8.Final approval of the fixed and variable compensation paid or awarded to Mr.Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31, 2023.
9.Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I.of the French Commercial Code.
10.Approval of the compensation policy for Mr.Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer.
11.Approval of the compensation policy for Mr.Pierre Broqua in his capacity as Deputy Chief Executive Officer.
12.Total compensation paid to members of the Board of Directors.
13.Approval of the compensation policy of the Company's directors.
14.Appointment of Mr.André Turenne, as Director of the Company.
15.Renewal of the Director's mandate of Ms.Martine Zimmermann.
16.Renewal of the Director's mandate of Mr.Heinz Maeusli.
17.Renewal of the Director's mandate of Ms.Lucy Lu.
18.Renewal of the company KPMG as Statutory Auditor.
19.Authorization granted to the Board of Directors to buyback the Company's shares.
20.Authorization to the Board of Directors to reduce the share capital by cancellation of shares.
21.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders’ preemptive subscription rights maintained.
22Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2- 1 of the French Code monétaire et financier.
23.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1 of the French Code monétaire et financier.
24.Authorization and/or delegation to the Board of Directors to set the issuance price on the capital increases by way of public offerings, without shareholders’ preemptive rights, pursuant to the terms and conditions set by the General Shareholders' Meeting, and up to the limit provided for by the laws and regulations in force at the time of issue.
25.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders’ preemptive subscription rights.
26.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the U.S.market called "At-the-market" or "ATM", without shareholders’ preemptive subscription rights.
27.Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders’ preemptive subscription rights.
28.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company.
29.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind within the limits set by legal and regulatory provisions, excluding the case of a public exchange offer initiated by the Company.
30.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights.
31.Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums.
32.Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers.
33.Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options.
34.Delegation of authority to the Board of Directors to decide on the issue of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons.
35.Decision to be taken in application of article L. 225-248 of the French Commercial Code (shareholders' equity less than half the share capital).
36.Creation of a new article 23 "Censeur" (non-voting director).
37.Power for formalities.
|
| 2024-04-03 |
详情>>
业绩披露：
2023年年报每股收益-2.43欧元,归母净利润-1.1亿欧元,同比去年增长-103.46%
|
| 2023-10-03 |
详情>>
业绩披露：
2023年中报每股收益-1.31欧元,归母净利润-5526.9万欧元,同比去年增长-87.57%
|
| 2023-04-17 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.Approval of the statutory financial statements for the financial year ended December 31st, 2022.
2.Approval of the consolidated financial statements for the financial year ended December 31st, 2022.
3.Appropriation of profit/loss for the financial year ended December 31st, 2022.
4.Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code.
5.Related-party agreements.
6.Final approval of the fixed and variable compensation paid or awarded to Mr. Frederic Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer for the financial year ended December 31st, 2022.
7.Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31st, 2022;.
8.Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code.
9.Approval of the compensation policy for Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer.
10.Approval of the compensation policy for Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer.
11.Approval of the compensation policy of the Company's directors.
12.Authorization granted to the Board of Directors to buyback the Company's shares.
13.Authorization to the Board of Directors to reduce the share capital by cancellation of shares.
14.Power for formalities.
|
| 2023-04-17 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.Approval of the statutory financial statements for the financial year ended December 31st, 2022.
2.Approval of the consolidated financial statements for the financial year ended December 31st, 2022.
3.Appropriation of profit/loss for the financial year ended December 31st, 2022.
4.Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code.
5.Related-party agreements.
6.Final approval of the fixed and variable compensation paid or awarded to Mr. Frederic Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer for the financial year ended December 31st, 2022.
7.Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31st, 2022;.
8.Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code.
9.Approval of the compensation policy for Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer.
10.Approval of the compensation policy for Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer.
11.Approval of the compensation policy of the Company's directors.
12.Authorization granted to the Board of Directors to buyback the Company's shares.
13.Authorization to the Board of Directors to reduce the share capital by cancellation of shares.
14.Power for formalities.
|
| 2023-03-30 |
详情>>
业绩披露：
2020年年报每股收益-0.99欧元,归母净利润-3362万欧元,同比去年增长-11.26%
|
| 2023-03-30 |
详情>>
业绩披露：
2022年年报每股收益-1.31欧元,归母净利润-5427.4万欧元,同比去年增长-9.35%
|
| 2022-12-19 |
股东大会：
将于2023-01-25召开股东大会
会议内容 ▼▲
- 1.Ratification of the appointment (cooptation) of Ms. Lucy Lu to replace a resigning Director.
2.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders’ preemptive subscription rights maintained.
3.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2 1° of the French Code monetaire et financier.
4.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French Code monetaire et financier.
5.Authorization to the Board of Directors to set the issuance price on the capital increases by way of public offerings, without shareholders’ preemptive rights, pursuant to the terms and conditions set by the General Shareholders' Meeting, and up to the limit of 10% of the share capital.
6.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders’ preemptive subscription rights.
7.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the US market called "At-the-market" or "ATM", without shareholders’ preemptive subscription rights.
8.Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders’ preemptive subscription rights.
9.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company.
10.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind up to a maximum of 10% of the share capital, excluding the case of a public exchange offer initiated by the Company.
11.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights.
12.Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums.
13.Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers.
14.Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options.
15.Delegation of authority to the Board of Directors to decide on the issue of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons.
16.Power for formalities.
|
| 2022-12-19 |
股东大会：
将于2023-01-25召开股东大会
会议内容 ▼▲
- 1.Ratification of the appointment (cooptation) of Ms. Lucy Lu to replace a resigning Director.
2.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders’ preemptive subscription rights maintained.
3.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2 1° of the French Code monetaire et financier.
4.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French Code monetaire et financier.
5.Authorization to the Board of Directors to set the issuance price on the capital increases by way of public offerings, without shareholders’ preemptive rights, pursuant to the terms and conditions set by the General Shareholders' Meeting, and up to the limit of 10% of the share capital.
6.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders’ preemptive subscription rights.
7.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the US market called "At-the-market" or "ATM", without shareholders’ preemptive subscription rights.
8.Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders’ preemptive subscription rights.
9.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company.
10.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind up to a maximum of 10% of the share capital, excluding the case of a public exchange offer initiated by the Company.
11.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights.
12.Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums.
13.Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers.
14.Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options.
15.Delegation of authority to the Board of Directors to decide on the issue of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons.
16.Power for formalities.
|
| 2022-09-22 |
详情>>
业绩披露：
2022年中报每股收益-0.72欧元,归母净利润-2946.6万欧元,同比去年增长-27.36%
|
| 2022-04-11 |
股东大会：
将于2022-05-19召开股东大会
会议内容 ▼▲
- 1.Approval of the statutory financial statements for the financial year ended December 31st, 2021;
2.Approval of the consolidated financial statements for the financial year ended December 31st, 2021;
3.Appropriation of profit/loss for the financial year ended December 31st, 2021;
4.Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code;
5.Related-party agreements;
6.Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer for the financial year ended December 31st, 2021;
7.Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31st, 2021;
8.Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code;
9.Approval of the compensation policy for Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer;
10.Approval of the compensation policy for Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer;
11.Approval of the compensation policy of the Company's directors;
12.Ratification of the appointment (cooptation) of Ms. Martine Zimmermann to replace a resigning Director;
13.Renewal of the director's mandate of Mr. Frédéric Cren;
14.Renewal of the Director's mandate of Mr. Pierre Broqua;
15.Appointment of the company Sofia BV, represented by Mr. Chris Buyse, as Director of the Company;
16.Renewal of the Director's mandate of the company CELL+, represented by Ms. Annick Schwebig;
17.Renewal of the Director's mandate of Ms. Martine Zimmermann;
18.Renewal of the Director's mandate of Mr. Heinz Maeusli;
19.Authorization granted to the Board of Directors to buyback the Company's shares;
20.Authorization to the Board of Directors to reduce the share capital by cancellation of shares;
21.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders’ preemptive subscription rights maintained;
22.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2- 1° of the French Code monétaire et financier;
23.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French Code monétaire et financier;
24.Authorization to the Board of Directors to set the issuance price on the capital increases by way of public offerings, without shareholders’ preemptive rights, pursuant to the terms and conditions set by the General Shareholders' Meeting, and up to the limit of 10% of the share capital;
25.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders’ preemptive subscription rights;
26.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the US market called "At-the-market" or "ATM", without shareholders’ preemptive subscription rights;
27.Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders’ preemptive subscription rights;
28.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company;
29.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind up to a maximum of 10% of the share capital, excluding the case of a public exchange offer initiated by the Company;
30.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights;
31.Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums;
32.Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers;
33.Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options;
34.Delegation of authority to the Board of Directors to decide on the issue of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons;
35.Amendment of Article 15 of the Company's Articles of Association to allow for a staggered renewal of the Directors' mandates;
36.Power for formalities.
|
| 2022-03-11 |
详情>>
业绩披露：
2021年年报每股收益-1.27欧元,归母净利润-4963.5万欧元,同比去年增长-47.64%
|
| 2021-09-20 |
详情>>
业绩披露：
2021年中报每股收益-0.6欧元,归母净利润-2313.6万欧元,同比去年增长-47.75%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-10 |
股东大会：
将于2021-04-16召开股东大会
会议内容 ▼▲
- 1.Approval of the statutory financial statements for the financial year ended December 31st, 2020;
2.Appropriation of profit/loss for the financial year ended December 31st, 2020;
3.Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code;
4.Related-party agreements;
5.Final approval of the fixed and variable compensation paid or awarded to Mr. Frederic Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer for the financial year ended December 31st, 2020;
6.Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31st, 2020;
7.Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code;
8.Approval of the compensation policy for Mr. Frederic Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer;
9.Approval of the compensation policy for Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer;
10.Approval of the compensation policy of the Company's Directors;
11.Renewal of the director's mandate of the company Sofinnova Partners, represented by Ms. Lucy Lu, for a period of 3 years;
12.Appointment of the company Lison Chouraki Audit (LCA) as second Statutory Auditor;
13.Appointment of the company R&Berg Audit as Alternate Auditor;
14.Authorization granted to the Board of Directors to buyback the Company's shares;
15.Authorization to the Board of Directors to reduce the share capital by cancellation of shares;
16.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders’ preemptive subscription rights maintained;
17.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2 1° of the French Code monétaire et financier;
18.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders’ preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French Code monétaire et financier;
19.Authorization to the Board of Directors to set the issuance price on the capital increases by way of public offerings, without shareholders’ preemptive rights, pursuant to the terms and conditions set by the General Shareholders' Meeting, and up to the limit of 10% of the share capital;
20.Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders’ preemptive subscription rights;
21.Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders’ preemptive subscription rights;
22.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company;
23.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind up to a maximum of 10% of the share capital, excluding the case of a public exchange offer initiated by the Company;
24.Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights;
25.Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums;
26.Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers;
27.Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options;
28.Delegation of authority to the Board of Directors to decide on the issue of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons;
29.Power for formalities.
|